RxDoctor Payments Data

Olufonso Ojo, MD

Internal Medicine · Lithonia, GANPI 1316991748

Payments from drug & device makers

$2,288in general payments, 2019–2025

Across 130 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$507
  • Novo Nordisk$403
  • Merck$250
  • Lilly USA, LLC$224
  • Sanofi-aventis U.S. LLC$158
  • Bayer$148
  • plus $598 from 14 others

What the payments were for

  • Food & beverage$2,288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,288 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$42,386
Medicare patients
97
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$93,774
TrulicityDulaglutide27$58,303
JardianceEmpagliflozin27$46,535
JanuviaSitagliptin Phosphate47$45,182
MounjaroTirzepatide22$38,598
JanumetSitagliptin Phos/Metformin Hcl27$31,022
EliquisApixaban44$30,880
RybelsusSemaglutide11$25,915
LinzessLinaclotide21$21,658
FarxigaDapagliflozin Propanediol23$15,522
GlyxambiEmpagliflozin/Linagliptin11$14,073
Tresiba Flextouch U-100Insulin Degludec16$3,509
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,190
Amlodipine Besylate577$2,871
Albuterol Sulfate HfaAlbuterol Sulfate84$2,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$403$119,68960 claims
Lilly USA, LLCTrulicity, Mounjaro$224$96,90149 claims
MerckJanuvia, Janumet$250$76,20474 claims
Boehringer IngelheimJardiance, Glyxambi$56$60,60738 claims
PfizerEliquis$30$30,88044 claims
AbbVieLinzess$107$21,65821 claims
AstraZenecaFarxiga$507$15,52223 claims
Sanofi-aventis U.S. LLCLantus$158$1,52512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Lithonia

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →